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With almost every third individual aﬀected in the general
population in industrialized countries and increasing prev-
alence among children and adolescents, nonalcoholic fatty
liver disease (NAFLD) represents the most common cause
of chronic liver diseases such as cirrhosis, liver failure, and
hepatocellular carcinoma and is therefore the most common
cause of liver transplantation. In addition, in recent years
NAFLD has emerged as a key player in human metabolism.
Several studies demonstrate that NAFLD is strongly associ-
ated with insulin resistance and precedes the manifestation
of type 2 diabetes and cardiovascular disease.
Of particular interest, the associations of ectopic fat
accumulation in the liver with insulin resistance and type
2 diabetes are stronger than the respective of visceral and
intramyocellularfat,implyingthatliverfatisanindependent
factor modifying the whole-body obesity-related metabolic
risk. Thus, fatty liver may be not simply another manifes-
tation of the metabolic syndrome, but it may itself induce
or worsen insulin resistance and type 2 diabetes. In other
words, fatty liver may be a determinant, not merely a marker
ofmetabolicdysfunction.Thoughcertainly,cause-and-eﬀect
relationships are hard to establish.
It is therefore why a concerted eﬀort of the academic dis-
ciplines is requested to study the responsible mechanisms
involved in the process of hepatic fat accumulation as well as
the mechanisms regulating the crosstalk between fatty liver
and other tissues important for regulation of metabolism in
humans. In this special issue, we have invited some papers
hoping to shed light on some aspects of this very interesting
ﬁeld.
In the ﬁrst paper of this issue “Diagnosis and evaluation
of nonalcoholic fatty liver disease,” epidemiology and tools for
diagnosing NAFLD are reviewed. Regarding epidemiology,
interesting data are provided on the interaction of NAFLD
and type 2 diabetes, when concurrently present. In terms of
diagnostic evaluation, of particular interest is the systematic
presentation of old and novel biomarkers as well as panel
markers(scores)andtheirsensitivity,speciﬁcity,positiveand
negative predictive values in estimating the amount of liver
fat and diﬀerentiating more progressive forms of NAFLD,
such as NASH and ﬁbrosis, from simple steatosis.
The second paper of this issue “Role of transcription
factor modiﬁcations in the pathogenesis of insulin resistance,”
evaluates the diverse types of posttranslational modiﬁcation
of transcription factors in insulin-sensitive tissues and their
putative role in the pathogenesis of insulin resistance. The
authors particularly focused on the liver, where a lot of tran-
scription factors have key roles in metabolic pathways crit-
ical for the pathogenesis of hepatic insulin resistance and
NAFLD. For instance, forkhead box protein 1 (FOXO1) and
cAMP response element binding protein (CREB) are major
tran-scription factors for gluconeogenic gene expression,
and sterol regulatory element-binding protein-1c (SREBP-
1c) and carbohydrate response element-binding protein
(ChREBP) are well known to regulate the expression of
genes coding for lipogenic enzymes in hyperinsulinemic and2 Experimental Diabetes Research
hyperglycemicstates.Thus,understandingthecircumstances
under which transcription factors undergo modiﬁcations
will enhance our understanding of the molecular mecha-
nisms leading to NAFLD and how it is related to insulin
resistance.
The third paper of this issue “Inhibition of aldose re-
ductase activates hepatic peroxisome proliferators-activated
receptor-α and ameliorates hepatosteatosis in diabetic db/db
mice,” examines the eﬀect of inhibiting aldose reductase, the
rate-limiting enzyme of the polyol pathway, on serum and
hepatictriglyceridelevelsindb/dbdiabeticmice.Thepolyol-
pathway is considered to be important in the development
of a variety of diabetic complications but was thought not
to play a signiﬁcant role in liver disease, because the hepatic
activity of aldose reductase is generally low. In this work, the
authors inhibited aldose reductase, both pharmacologically
and by a short-hairpin RNA, and found that this leads to
a signiﬁcant reduction in serum and hepatic triglycerides
under hyperglycemia, possibly by activating PPARα and
therebylipidoxidation.Theseﬁndingsindicatethatthepoly-
ol pathway may be upregulated under certain conditions and
may contribute to the development of NAFLD.
The fourth paper of this issue “Cholesterol synthesis is
associated with hepatic lipid content and dependent on fruc-
tose/glucose intake in healthy humans,” reports on the associ-
ation of liver and visceral fat with cholesterol homeostasis.
Obesity, insulin resistance, and type 2 diabetes have been
showntoindependentlycorrelatewithincreasedendogenous
cholesterol synthesis. However, the associations of body
fat distribution with cholesterol metabolism have not been
extensively studied. The authors found that visceral and
liver fat are associated with cholesterol biosynthesis but not
cholesterol intestinal absorption. This suggests that people
with high liver fat and hypercholesterolemia will probably
proﬁt from statin treatment. The impact of high-fructose
diet, which is thought to promote liver fat accumulation and
hypercholesterolemia, on cholesterol homeostasis was also
studied. Of interest, high-glucose diet appeared to stimulate
cholesterol synthesis more than high-fructose diet did.
In the ﬁfth article of this issue “Predictors of impaired
glucose regulation in patients with nonalcoholic fatty liver dis-
ease”, the authors set out to ﬁnd commonly measured demo-
graphic and laboratory parameters predicting an abnormal
oral glucose tolerance test (OGTT) response (impaired glu-
cose tolerance or diabetes mellitus) in patients with ultra-
sonography-diagnosed fatty liver. NAFLD is known to be
closely associated with insulin resistance and type 2 diabetes;
however, the characteristics of NAFLD patients having also
hyperglycemia compared to NAFLD patients with normal
glucose tolerance are not known. The authors found that if
an OGTT is performed in patients with NAFLD and elevated
liver enzymes, but no history of diabetes, almost half of them
will display impaired glucose regulation, more likely those
who are older, have higher BMI and lower HDL-cholesterol.
Thus, at least those NAFLD patients with these characteris-
tics should undergo further evaluation with an OGTT.
The ﬁnal paper of this issue “The role of metformin in
the management of NAFLD” is a review article summarizing
the mechanism of action of metformin, the clinical studies
performed so far on the use of metformin in patients with
NAFLD, and the potential beneﬁts of using metformin in
NAFLD beyond its action in the liver. Currently, metformin
is not considered to be an established treatment for NAFLD
patients, probably because the existing clinical studies have
been mostly small in sample size and short in duration and
have provided in part controversial results. Most impor-
tantly, true randomized and controlled trials are lacking.
Nevertheless,thehighbeneﬁt-riskratioofmetformin,aswell
asitspleiotropicfavourableeﬀects(e.g.,inpromotingweight
loss and lowering the risk of cancer), makes it an attractive
treatment option for all patients with metabolic disturban-
ces.Indeed,inthisreviewtheauthorsprovideargumentation
indicating that metformin may be of beneﬁt in the treatment
of both diabetic and nondiabetic patients with NAFLD.
The data presented and reviewed in this special issue
highlight some novel or hitherto not elaborately studied as-
pects of NAFLD pathophysiology and treatment. Moreover,
and perhaps more importantly, they underscore the com-
plexity of factors and mechanisms regulating liver fat accu-
mulation and depletion. We hope that they will encourage
future eﬀorts and research into understanding this very in-
teresting and highly prevalent metabolic disorder.
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